



Application No.: 09/887540

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: sequence in Figs 3A-3B does not have

if necessary SEQ ID NO.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

0300
HL 1600
PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

| | |
|--|--------------------|
| Application Number | 09/887,540 |
| Filing Date | June 21, 2001 |
| First Named Inventor | KLEIN |
| Group Art Unit | 1632 |
| Examiner Name | WILSON, Michael C. |
| Total Number of Pages in This Submission | 13 |
| Attorney Docket Number | R-193 |

ENCLOSURES (check all that apply)

| | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers (for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input checked="" type="checkbox"/> Drawing(s) new Fig. 3B | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input checked="" type="checkbox"/> Amendment / Reply Preliminary | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/ Incomplete Application | <input type="checkbox"/> Remarks | |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

RECEIVED
NOV 20 2002
TECH CENTER 1600/2900
Response to Restriction Requirement dated 10/2/02
Response to Notice to Comply w/ Requirements for
Applications Containing Nucleotide Sequence Dis-
closures dated 10/2/02 and Copy of Notice

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|-------------------------------|------------------------------------|
| Firm or Individual name | Mariette A. Lapiz, Reg. No. 44,202 |
| Signature | |
| Date | 11/01/02 |

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class
mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

11/1/02

| | |
|-----------------------|---------------------|
| Typed or printed name | Deborah A. Mojarrro |
| Signature | |
| Date | 11/1/02 |

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Robert KLEIN

Group Art Unit: 1632

Serial No.: 09/887,540

Examiner: Wilson, Michael C.

Filed: June 21, 2001

Attorney Docket No.: R-193

For: TRANSGENIC MICE CONTAINING LRP5 GENE DISRUPTIONS

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 2, 2002 regarding the above-captioned application, Applicants submit herewith:

1. A Preliminary Amendment under 37 C.F.R. §1.115 with an amendment to Figure 3B of the above-referenced application;
2. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 2, 2002.

The Sequence Listing submitted on December 19, 2001, in computer readable format (CRF) and paper, contains all sequences disclosed in the application. Therefore, Applicants believe that a substitute Sequence Listing in CRF is not required. Moreover, the content of the paper and computer readable copies of the Sequence Listing submitted on July 1, 2002 are identical. The sequence listing submitted in this application merely presents nucleotide and/or amino acid sequences that appeared in the application as originally filed in accordance with 37 C.F.R. §1.821-1.825, thus no new matter has been introduced into the application.

Accordingly, Applicants respectfully request the entry of the paper and computer readable forms of the sequence listing into the application.

Respectfully submitted,

Date: 11/01/02

Mariette A. Lapiz
Mariette A. Lapiz, Reg. No. 44,202

DELTAGEN, INC.
740 Bay Road
Redwood City, CA 94063
Tel. (650) 569-5100
Fax (650) 569-5280

Enclosures

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence and its listed enclosures is being deposited with the United States Postal Service as First Class Mail, postage paid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, Box NF Amendment on **November 1, 2002**.

Name: **Deborah A. Mojarrro**

Signed: Deborah A. Mojarrro

Date: 11/1/02